{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:10:26Z","timestamp":1791090626614,"version":"4.1.0"},"reference-count":34,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,8]]},"abstract":"<jats:p content-type=\"fine-print\"><jats:italic>Object.<\/jats:italic> The management of certain meningiomas of the skull base and those involving the dural venous sinuses remains a challenge. In recent reports it has been suggested that hydroxyurea chemotherapy can cause regression of unresectable and recurrent meningiomas. The authors report their experience in using hydroxyurea for the treatment of patients with recurrent or unresectable meningiomas.<\/jats:p>\n<jats:p content-type=\"fine-print\"><jats:italic>Methods.<\/jats:italic> Hydroxyurea was administered at a dosage of approximately 20 mg\/kg\/day to 11 women and nine men (median age 59 years, range 31\u201375 years) with recurrent or unresectable intracranial meningiomas (12 basal, two parasagittal, and six multiple). In 16 patients the meningiomas were benign, in three they had atypical features, and in one the meningioma was malignant. All patients had measurable residual disease. Four patients with benign meningiomas had previously received radiotherapy (two were treated with conventional fractionated radiotherapy and two with stereotactic radiosurgery), three with atypical meningiomas received conventional fractionated radiotherapy, and the one with a malignant meningioma received conventional radiotherapy with additional stereotactic radiosurgery. Tumor enlargement was documented in all patients on neuroimages obtained before initiation of hydroxyurea therapy.<\/jats:p>\n<jats:p content-type=\"fine-print\">All patients were evaluable for response to therapy. In 12 patients with benign meningiomas, the disease had stabilized on neuroimages obtained posttreatment (median duration of treatment 122 weeks, range 8\u2013151 weeks), and two of these showed clinical improvement. One patient with a benign meningioma experienced a minor partial response that was noted after 39 weeks of treatment and was confirmed on neuroimaging and clinical evaluations. In three others with benign meningiomas, progression was confirmed on neuroimages obtained after 41, 55, and 66 weeks, respectively; the 1-year freedom from progression rate was 0.93 (standard error 0.07) in patients with benign meningiomas. In three patients with atypical meningiomas, the tumors had progressed on neuroimages obtained after 12, 19, and 45 weeks, respectively. In the patient with a malignant meningioma, progression was confirmed on neuroimages obtained at 24 weeks. Hydroxyurea has been reasonably well tolerated, although one patient discontinued therapy because of moderate myelosuppression.<\/jats:p>\n<jats:p content-type=\"fine-print\"><jats:italic>Conclusions.<\/jats:italic> Although tumor regression appears uncommon, these results indicate that hydroxyurea may arrest progression of unresectable or recurrent benign meningiomas.<\/jats:p>","DOI":"10.3171\/jns.2002.97.2.0341","type":"journal-article","created":{"date-parts":[[2009,5,13]],"date-time":"2009-05-13T17:45:03Z","timestamp":1242236703000},"page":"341-346","source":"Crossref","is-referenced-by-count":144,"title":["Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningiomas"],"prefix":"10.3171","volume":"97","author":[{"given":"Warren P.","family":"Mason","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Gentili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramanian","family":"Hariharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene R.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Abrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"key":"b1","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3171\/jns.1994.81.2.0284","article-title":"Necrosis in a meningioma following systemic chemotherapy. Case report.","volume":"81","author":"Bernstein","year":"1994"},{"key":"b2","series-title":"Neurosurgery","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/00006123-199304000-00023","article-title":"Meningiomas.","volume":"32","author":"Black","year":"1993"},{"key":"b3","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3171\/jns.1996.84.5.0733","article-title":"Adjuvant combined modality therapy for malignant meningiomas.","volume":"84","author":"Chamberlain","year":"1996"},{"key":"b4","series-title":"Biochem Biophys Res Commun","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0006-291X(68)90266-0","article-title":"Effect of hydroxyurea on ribonucleotide reductase.","volume":"33","author":"Elford","year":"1968"},{"key":"b5","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3171\/jns.1994.80.2.0195","article-title":"Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990.","volume":"80","author":"Goldsmith","year":"1994"},{"key":"b6","series-title":"J Neurooncol","first-page":"73","article-title":"A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study.","volume":"15","author":"Goodwin","year":"1993"},{"key":"b7","series-title":"Hum Reprod","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/humrep\/9.suppl_1.202","article-title":"Role of antiprogestational therapy for meningiomas.","volume":"9","author":"Grunberg","year":"1994"},{"key":"b8","series-title":"Proc Am Soc Clin Oncol","first-page":"56a","article-title":"Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma.","volume":"20","author":"Grunberg","year":"2001"},{"key":"b9","series-title":"J Neurooncol","first-page":"61","article-title":"Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma.","volume":"8","author":"Grunberg","year":"1990"},{"key":"b10","series-title":"Teratology","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/tera.1420180113","article-title":"Investigation of the effect of hydroxyurea on the cell cycle and the development of necrosis in the embryonic CNS of mice.","volume":"18","author":"Herken","year":"1978"},{"key":"b11","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/1097-0142(19861001)58:7<1466::AID-CNCR2820580715>3.0.CO;2-W","article-title":"Proliferative potential of human meningiomas of the brain. A cell kinetics study with bromodeoxyuridine.","volume":"58","author":"Hoshino","year":"1986"},{"key":"b12","series-title":"Neurosurgery","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00006123-199702000-00007","article-title":"The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B.","volume":"40","author":"Kaba","year":"1997"},{"key":"b13","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/1097-0142(197204)29:4<1052::AID-CNCR2820290454>3.0.CO;2-7","article-title":"Hydroxyurea therapy in chronic myelogenous leukemia.","volume":"29","author":"Kennedy","year":"1972"},{"key":"b14","series-title":"JAMA","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1001\/jama.1966.03100120106029","article-title":"Metabolic and therapeutic effects of hydroxyurea in chronic myeloid leukemia.","volume":"195","author":"Kennedy","year":"1966"},{"key":"b15","series-title":"Cancer Res","first-page":"1301","article-title":"Action of hydroxyurea on the nucleic acid metabolism and viability of HeLa cells.","volume":"27","author":"Kim","year":"1967"},{"key":"b16","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3171\/jns.1999.91.1.0044","article-title":"Long-term outcomes after meningioma radiosurgery: physician and patient perspectives.","volume":"91","author":"Kondziolka","year":"1999"},{"key":"b17","series-title":"Cancer Res","first-page":"1559","article-title":"Inhibition of ribonucleotide diphosphate reductase by hydroxyurea.","volume":"28","author":"Krakoff","year":"1968"},{"key":"b18","series-title":"J Neurol Neurosurg Psychiatry","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1136\/jnnp.55.6.486","article-title":"Mifepristone (RU 486) treatment of meningiomas.","volume":"55","author":"Lamberts","year":"1992"},{"key":"b19","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/1097-0142(19930801)72:3<639::AID-CNCR2820720304>3.0.CO;2-P","article-title":"Epidemiology of intracranial meningioma.","volume":"72","author":"Longstreth","year":"1993"},{"key":"b20","series-title":"J Clin Oncol","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma.","volume":"8","author":"Macdonald","year":"1990"},{"key":"b21","series-title":"Surg Neurol","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/0090-3019(86)90081-9","article-title":"Recurrence of meningiomas after operation.","volume":"25","author":"Marks","year":"1986"},{"key":"b22","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/0360-3016(95)02166-3","article-title":"Radiotherapy for atypical or malignant intracranial meningioma.","volume":"34","author":"Milosevic","year":"1996"},{"key":"b23","series-title":"J Neurooncol","first-page":"157","article-title":"The role of radiotherapy in the treatment of subtotally resected benign meningiomas.","volume":"37","author":"Miralbell","year":"1992"},{"key":"b24","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3171\/jns.1985.62.1.0018","article-title":"Meningioma: analysis of recurrence and progression following neurosurgical resection.","volume":"62","author":"Mirimanoff","year":"1985"},{"key":"b25","series-title":"Common Toxicity Criteria.","year":"1998"},{"key":"b26","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3171\/jns.1994.80.2.0191","article-title":"Meningiomas: a quest for the optimum therapy.","volume":"80","author":"Newman","year":"1994"},{"key":"b27","series-title":"J Neurooncol","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1023\/A:1026770624783","article-title":"Hydroxyurea chemotherapy for unresectable or residual meningioma.","volume":"49","author":"Newton","year":"2000"},{"key":"b28","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3171\/jns.1997.86.5.0793","article-title":"Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases.","volume":"86","author":"Palma","year":"1997"},{"key":"b29","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3171\/jns.1985.62.4.0502","article-title":"Radiation therapy for incompletely resected meningiomas.","volume":"62","author":"Petty","year":"1985"},{"key":"b30","series-title":"Meningiomas.","first-page":"22","article-title":"Etiology and biology of meningiomas","author":"Rachlin","year":"1991"},{"key":"b31","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3171\/jns.1989.71.5.0665","article-title":"Incidence and clinicopathological features of meningioma.","volume":"71","author":"Rohringer","year":"1989"},{"key":"b32","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3171\/jns.1997.86.5.0845","article-title":"Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.","volume":"86","author":"Schrell","year":"1997"},{"key":"b33","series-title":"J Neurosurg","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3171\/jns.1997.86.5.0840","article-title":"Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.","volume":"86","author":"Schrell","year":"1997"},{"key":"b34","series-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0360-3016(98)90008-6","article-title":"The meningioma controversy: postoperative radiation therapy.","volume":"15","author":"Taylor","year":"1988"}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/97\/2\/article-p341.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/97\/2\/article-p341.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/97\/2\/article-p341.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T01:19:57Z","timestamp":1679275197000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/97\/2\/article-p341.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8]]},"references-count":34,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3171\/jns.2002.97.2.0341","relation":{},"ISSN":["0022-3085"],"issn-type":[{"value":"0022-3085","type":"print"}],"subject":[],"published":{"date-parts":[[2002,8]]}}}